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EVALUATION OF METHOTREXATE POLYGLUTAMATES AS A BIOMARKER 
 




  Methotrexate (MTX) is an antagonist of folic acid metabolism that 
was initially designed to treat malignancies, including childhood leukemia. After 
its anti-inflammatory properties were discovered, use of MTX became 
widespread in the treatment algorithms for several autoimmune illnesses, 
including the inflammatory bowel diseases (IBD), Crohn’s disease (CD) and 
ulcerative colitis (UC). The specific cause(s) of IBD in general, and CD in 
specific, have not yet been fully elucidated.  However, most investigators agree 
that the pathogenesis is likely due to a combination of genetic vulnerability and 
precipitating environmental exposures. Some of these identifiable modifiers 
include adherence to a low fiber diet, vitamin D deficiency, smoking, and an 
alteration in the diversity of the gut microbiome in response to viral or bacterial 
illness or antibiotic medications. Disease activity in patients with CD, particularly 
during clinical trials, is assessed using composite indices, including the Crohn’s 
Disease Activity Index (CDAI), Crohn’s Disease Endoscopic Index of Severity 
(CDEIS), and the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).  
 A wide range of medications is used to induce and maintain long-term 
remission in patients with active CD. These include corticosteroids, 
immunosuppressive agents (thiopurines and MTX) and several classes of 
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biologics such as TNF-inhibitors, anti-IL-12/23 and anti-adhesion molecules. 
TNF-inhibitors are often used as first-line biologic therapies in patients with IBD 
because they have been in widespread use for over two decades and therefore 
afford the clinician a more data-driven consideration of risk to benefit ratio when 
discussing treatment options with their patients.  
However, there is a relatively high rate of primary non-response and 
acquired secondary loss of response to TNF-inhibitors. A secondary loss of 
response often results from the production of neutralizing antibodies, referred to 
as Antibodies to Infliximab (ATI). In response, concomitant low-dose oral MTX 
therapy has been employed by clinicians to reduce the immunogenicity of 
biologic therapy. In addition, previous studies have also demonstrated the 
efficacy of MTX monotherapy in maintaining clinical remission in patients with CD 
when delivered at relatively higher doses. However, there is no consensus on the 
proper dosing or route of administration (oral or parenteral) of MTX. This 
knowledge gap has resulted in inconsistent clinical practice across physicians 
and institutions.   
Pharmacologic studies have identified the metabolic pathways 
underpinning the mechanism of action of MTX. It is generally understood that 
MTX in its native form is free to move across cell membranes in a bidirectional 
manner. It is only after MTX has been glutamated (MTX-PG) that it is “caged” 
within the cell and can exert its effects. MTX can be glutamated on up to five 
discrete sites, each contributing to its stereospecificity and membrane 
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permeability. A better understanding of this process may inform the development 
of rational dosing and pharmacokinetic-based treatment algorithms that provide 
patients with a sufficient MTX (and subsequently MTX-PG) level required to 
achieve anticipated clinical efficacy but not so high as to contribute undo 
morbidity to treated patients. Therefore, optimizing MTX/MTX-PG dosing can 
significantly advance the utility of this immunomodulatory pathway to treat IBD 
and other autoimmune disorders.   
 MTX can be administered orally or parenterally, the latter being delivered 
by either subcutaneous or intramuscular injection. Previous studies have 
demonstrated increased bioavailability of the drug at higher doses when 
delivered via the parenteral route. The native form of MTX has a short half-life 
and is eliminated from the body within 24 hours. Instead, it is the active 
metabolites of MTX which are retained for more extended periods of time and are 
ultimately responsible for the anti-inflammatory effects in the body. A MTX 
molecule can have anywhere from 1 and 5 glutamyl groups attached to it, 
denoted as MTX-PG1, MTX-PG 2, MTX-PG3, MTX-PG 4, and MTX-PG 5. The 
mechanism(s) by which MTX-PG moieties contribute anti-inflammatory activity is 
not fully understood but remains an area of active research.  
Several studies have explored the association between disease activity 
and erythrocyte MTX-PG levels. While initial results were mixed, more recent 
prospective cohort studies in patients with Rheumatoid Arthritis (RA) found an 
inverse relationship between intracellular levels of longer-chain MTX-PG (MTX-
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PG3, MTX-PG4, and MTX-PG5) and disease activity. This finding has raised the 
possibility that monitoring MTX-PG levels could be used as a clinical tool to 
optimize MTX therapy for patients. However, several key issues persist, including 
high interpatient variability in MTX-PG levels. Similar studies in patients with CD 
have thus far been scarce. More prospective studies are needed to explore the 
utility of MTX-PG pharmacokinetics as a useful biomarker and clinical tool to 
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Origins of Methotrexate in Treating Autoimmune Diseases 
Methotrexate (4-amino-10-methylfolic acid, MTX) is an antagonist of folic 
acid metabolism used to treat many malignant and non-malignant diseases 
(Bedoui et al., 2019). The origin of MTX can be traced back to the successful use 
of aminopterin in the treatment of childhood leukemia in 1948 (Farber and 
Diamond, 1948). Due to the challenges associated with manufacturing 
aminopterin and its associated toxicity, this compound was modified into the 
present form known as methotrexate (Weinblatt, 2013; Bedoui et al., 2019). From 
the 1950s to the 1980s, several studies demonstrated the efficacy of MTX in 
treating autoimmune diseases, including rheumatoid arthritis (RA) and psoriasis.  
These data culminated in the US Food and Drug Administration (FDA) approving 
MTX as a therapy for RA in 1988 (Weinblatt, 2013). In addition to its use in RA 
and psoriasis, MTX is currently used to treat several other autoimmune diseases, 
including juvenile idiopathic arthritis, multiple sclerosis, and Crohn’s disease. 
Overview of Crohn’s Disease 
Crohn’s Disease (CD) and ulcerative colitis (UC) are chronic inflammatory 
intestinal disorders that fall under the umbrella term of inflammatory bowel 
disease (IBD). The Centers for Disease Control and Prevention (CDC) estimates 
that as of 2015, 3.1 million (1.3%) U.S. adults had received a diagnosis of IBD, 
up from 1.8 million (0.9%) U.S. adults in 1999 (Dahlhamer et al., 2016). The 
prevalence of CD in the United States is 201 per 100,000 (Kappelman et al., 
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2007). While the cause(s) of IBD remain unknown, risk factors include genetics 
and environmental factors, including smoking, low-fiber diet, disturbed sleep, 
increased stress, and a sedentary lifestyle (Gajendran et al., 2018). Additionally, 
appendectomy, vitamin D deficiency, and alterations in gut microbiota associated 
with medications or bacterial infections have been associated with an increased 
incidence of CD (Gajendran et al., 2018). Many of these factors are linked, and it 
is consequently difficult to quantify the degree to which each factor may 
individually contribute to the diagnosis of CD in a particular patient.  
Classifying Disease Activity in Patients with Crohn’s Disease 
Several classification systems are presently in use to categorize the 
severity of disease activity in patients with CD. Many previous studies have 
employed the Crohn’s Disease Activity Index (CDAI), detailed in Table 1. This 
index was developed in 1976 and incorporates eight variables with their 
respective scores and multipliers based on the patient’s symptoms and medical 
history (Best et al., 1976). In 2010, the European Crohn’s and Colitis 
Organization (ECCO) published an update on the European evidence-based 
consensus document that outlines standards for use in the diagnosis and 
management of CD (Van Assche et al., 2010). This document established formal 
criteria for classifying disease activity (mild, moderate, or severe) based on CDAI 
scoring. Mild disease is characterized by a CDAI score ranging from 150-220 
while moderate and severe disease activity are characterized by CDAI’s of 220-
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450 and >450, respectively. Agreed-upon definitions that form the basis for 
treatment decisions are detailed in Table 2.  
 
Table 1. Crohn’s Disease Activity Index (CDAI). The table is adapted from 
(Best et al., 1976) 
 
Variables Scoring  Multiplier 
Total number of 
liquid stools over 
7 days 
N/A x2 
Pain in abdomen 
(sum over each 
of 7 days) 
0=none; 1=mild; 2=moderate; 
3=severe x5 
Well-being (sum 
over each of 7 
days) 
0 = well; 1 = under par; 2 = poor; 3 





aphtous stomatitis;  
arthritis/arthralgia; erythema 





drugs used in last 
7 days 
0=no; 1=yes x30 

















Table 2. Definitions of commonly used terms with Crohn’s Disease. Table 
adapted from (Van Assche et al., 2010) 
Term  Definition 
Response Reduction of CDAI by 100 from baseline.  
Remission  CDAI ≤ 150 
Relapse Return of symptoms in a patient who is previously in 
remission.  
Recurrence The reappearance of lesions after surgical resection 
Steroid-refractory 
disease 
Continued active disease after 4-week prednisolone 




1. Unable to reduce prednisolone (10mg/day) or 
budesonide (3 mg/day) within the first 3 months of 
starting steroids, without presence of active disease. 
2. Relapse <3 months of stopping steroids.  
Extensive Crohn’s 
disease 
Intestinal CD, >100cm in extent, regardless of location 
within the intestine. The inflammation area can be 
discontinuous. 
Localized CD Intestinal CD, <30cm in extent, usually in the ileocecal 
region.  
 
While the CDAI has been the standard measure of disease severity in 
clinical trials for CD medications, it does have a few limitations. CDAI scoring can 
have highly variable placebo response and remission rates (Su et al., 2004). The 
index also relies heavily on the clinical assessment of patients by physicians, and 
it does not include measures of mucosal healing or relevant biomarkers, which 
are more objective measures of disease activity. Therefore, many recent clinical 
trials have included C-reactive protein (CRP) measurements in conjunction with 
CDAI scores (Gajendran et al., 2018).  
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Endoscopic evaluation allows for a more direct and objective measure of 
disease activity. Crohn’s Disease Endoscopic Index of Severity (CDEIS) and the 
Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to 
assess disease activity in the mucous layer of the GI tract. CDEIS was 
developed in 1989 and relies on the identification (presence or absence) of 
aphthous lesions in five different bowel segments and the presence of ulcerated 
or non-ulcerated stenosis (Mary and Modigliani, 1989). The scores range from 0 
to 44 (44 = most severe). This index is detailed in Table 3.  
 
Table 3. Crohn’s Disease Endoscopic Index of Severity (CDEIS). Table 

















Rectum     
Sigmoid + left 
colon 
    
Transverse 
colon 
    
Right colon     
Ileum     
Total Total A Total B Total C Total D 
Total E = Total A + Total B + Total C + Total D 
Number of segments examined = n 
Total F = Total E / n 
G = 3 (ulcerated stenosis present anywhere) or 0 (no ulcerated stenosis) 
H = 3 (non-ulcerated stenosis present anywhere) or 0 (no non-ulcerated 
stenosis) 




The Simple Endoscopic Score for Crohn’s Disease (SES-CD) was 
developed in 2004 as a more straightforward and easier-to-calculate version of 
the CDEIS (Daperno et al., 2004). It looks at just four variables in the same five 
regions of the intestine as the CDEIS. Scores with this index range from 0 to 60 
(60 = most severe). This index is detailed in Table 4. Both endoscopic indices 
(CDEIS and SES-CD) are poorly correlated with the more symptom-based CDAI. 
This finding suggests that symptom resolution is poorly correlated with mucosal 
healing in patients with CD or that the timeline for symptom resolution is different 
than the timeline for mucosal healing. Another confounding variable is the 
inability to examine more distal regions of the small intestine using standard 
endoscopic technique. The Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) has also been used to gauge the quality of life in patients with IBD (see 
Appendix I).  
 
Table 4. Simplified Endoscopic Activity Score for Crohn's Disease (SES-
CD). Table adapted from (Daperno et al., 2004) 
 
 Presence 











Ileum     
Right 
colon 
    
Transverse 
colon 
    
Left colon     
Rectum     
Total Total A Total B Total C Total D 
SES-CD = Total A + Total B + Total C + Total D 
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Medications for Crohn’s Disease 
Medical management of CD is typically divided into two phases. The first 
phase involves bringing patients with active disease into clinical remission using 
“induction therapy.” After patients are in remission, the second phase involves 
maintaining remission using “maintenance therapy.” Some medications, such as 
Tumor Necrosis Factor (TNF) inhibitors, can be used for both induction and 
maintenance therapy. Other medications like corticosteroids and methotrexate 
are more suited for either induction or maintenance of remission, respectively. 
Given the complex and heterogeneous nature of CD, treatment is often focused 
on a combination of resolving clinical symptoms and mucosal healing. In clinical 
trials, the efficacy of medications is typically assessed using a combination of the 
indices mentioned previously, including the CDAI, CDEIS, and SES-CD.  
The choice of medications is typically made by clinicians based on 
variables, including disease type (CD vs. UC), severity, and location. The 
Montreal classification system was subsequently developed in 2005 as a 
modified version of the previously used Vienna classification developed in 1998 








Table 5. Montreal Classification of Inflammatory Bowel Disease. Table 
adapted from (Silverberg et al., 2005) 
 
Age of Diagnosis Location  Disease behavior 
A1 < 16 L1: ileal  B1: non-stricturing, non-
penetrating 
A2 17 – 40 L2: colonic  B2: stricturing 
A3 > 40 L3: ileocolonic  B3: penetrating 
 L4: upper disease 
modifier or isolated 
upper disease 




Before the widespread use of biologic therapy, patients with CD were 
treated using combinations of corticosteroids, aminosalicylates, and 
immunomodulators (Sulz et al., 2020). Corticosteroids such as prednisolone and 
budesonide are useful for the induction of remission, but there is no data to 
support their continued use after remission has been achieved (Gajendran et al., 
2018). Additionally, corticosteroids are often accompanied by many well-known 
side effects that make them undesirable for long-term use (Sulz et al., 2020). 
Common immunomodulators for maintenance treatment in patients with CD 
include thiopurines [Azathioprine (AZA) and 6-mercaptopurine (6-MP)] and MTX, 
which is a folate antagonist (Patel et al., 2014; Chande et al., 2015). Adverse 
events leading to discontinuation of the drug have been more common in 
patients receiving AZA (10%) than placebo.  However, this difference was not 
found to be statistically significant. (Chande et al., 2013). MTX given orally at 
lower doses (12.5-15 mg/week) is also not significantly more effective than 
placebo. However, higher doses of MTX (15-25 mg/week) given parenterally 
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appear to be superior to placebo (Chande et al., 2014). Importantly, there is a 
lack of large-scale studies evaluating the safety and efficacy of high-dose oral 
MTX treatment in maintenance and remission of Crohn’s disease.  
Infliximab was the first TNF inhibitor biologic approved to treat patients 
with IBD in 1998 (Kornbluth, 1998). Since then, other TNF-inhibitors, including 
adalimumab, certolizumab pegol, and golimumab, have been used to treat IBD 
as both induction and maintenance therapy (Gajendran et al., 2018). While 
infliximab is administered intravenously, the rest of the anti-TNF agents are 
designed to be delivered by subcutaneous injection. These agents bind to and 
inhibit the activity of TNF, an important pro-inflammatory cytokine. While biologic 
therapy with TNF-inhibitors has drastically changed the treatment of many 
inflammatory diseases, including IBD, many patients with CD fail to derive any 
benefit from them. In clinical trials, 20-40% of patients had primary non-response 
to anti-TNF induction therapy, and 23-46% exhibited a secondary loss of 
response (Ben-Horin et al., 2014).  
While there may be several mechanisms at play for this secondary loss of 
response, one factor is developing neutralizing antibodies to the anti-TNF 
therapy. These antibodies (ATI) reduce the efficacy of anti-TNF therapy and 
increase the likelihood of infusion reactions (Baert et al., 2013). One possible 
way to combat this is to co-administer immunosuppressives such as AZA, 6MP, 
and MTX in conjunction with anti-TNF therapy. While evidence on this has been 
somewhat mixed in the past, recent evidence shows that co-treatment with 
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immunomodulators is superior to biologic monotherapy, particularly in patients 
with particularly complicated cases of CD (such as B2: stricturing; B3: 
penetrating) and early in the course of the disease (Ananthakrishnan et al., 
2017). However, this is still an active area of research.  
Anti-adhesion molecules are among the newest class of agents available 
to treat patients with complicated CD. There are currently two anti-adhesion 
agents, natalizumab (Tysarbi™) and vedolizumab (Entyvio™) (Targan et al., 
2007; Sandborn et al., 2013) that the FDA has approved for use in patients with 
IBD. These monoclonal antibody molecules bind to the α4β7 integrins expressed 
on endothelial cells in response to local tissue inflammation.  This competitive 
blockade prevents leukocyte adhesion and subsequent migration into inflamed 
gastrointestinal mucosa and submucosa (Gajendran et al., 2018).  
Finally, ustekinumab (Stelara™) is a monoclonal antibody that targets the 
p40 subunits of interleukin-12 and interleukin-23 (IL-12 and IL-23) (Sandborn et 
al., 2012). In doing so, it suppresses the T-helper cell-driven pathways that lead 
to inflammation in the gastrointestinal tract.  
Current ECCO guidelines do not articulate a preferred choice for first-line 
biologic (anti-TNF, anti-adhesion, and anti-IL-12/23) therapy. However, the use of 
anti-TNF agents as first-line biologic is common, as clinicians are more familiar 
with their use and can more confidently explain the relative risk to benefit ratio to 
their patients. Further, the growing availability of biosimilars can drive down the 
cost to third-party payors (Sulz et al., 2020). Figure 1 shows a summary of the 
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currently used medications to treat CD and their typical dosage. Figure 2 shows 
a sample treatment algorithm for CD.  
 





Figure 2. Treatment algorithm for endoluminal Crohn’s disease. In this 
algorithm, the disease's location and severity are not delineated to avoid 





Specific aims for this thesis include the following:  
 
1. A comprehensive review of the literature concerning the anti-inflammatory 
mechanisms of action of methotrexate and its active metabolites, 
methotrexate polyglutamates.  
2. Examination of the current literature regarding the use of methotrexate 
polyglutamate as a biomarker in treating chronic, inflammatory diseases. 
3. A summary of the data supporting the validity of using methotrexate 
polyglutamate levels as a clinical tool in managing children and adults with 







METHOTREXATE POLYGLUTAMATES – PHARMACOKINETICS AND 
MECHANISM OF ACTION 
 
Pharmacokinetics and Toxicity of Methotrexate 
Methotrexate (MTX) is a folate antagonist (see Figure 3a) that has been 
used in the treatment of malignant diseases but also found use, at lower doses, 
in the treatment of inflammatory diseases like juvenile idiopathic arthritis (JIA), 
Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis. MTX itself has a 
short half-life and is undetectable in the serum after 24 hours (Tishler et al., 
1989). However, MTX can be taken up by cells via a reduced folate carrier.  
Once inside the cell, glutamyl groups are added to MTX by the enzyme 
polyglutamyl synthetase (Chabner et al., 1985). The products of this glutamation 
reaction are called methotrexate polyglutamates (MTX-PG) and are denoted as 
MTX-PGn (n = number of glutamate groups added) (Danila et al., 2010). MTX-
PG1 to MTX-PG 5 account for 99.6% of the total intracellular MTX-PG 
concentration, with MTX-PG3 being the most abundant (Becker et al., 2010). 
Upon polyglutamation, these molecules are “caged” intracellularly due to their 
size and negative charge.  MTX-PG metabolites inhibit several enzymes involved 
in inflammatory processes (Kremer, 2004). Long-chain MTX-PG moieties (MTX-
PG3,4 & 5) are the most potent inhibitors of the enzyme dihydrofolate reductase 
(DHFR) due to their greater affinity and slower dissociation rate from the enzyme 
(Jolivet and Chabner, 1983). As a counter-regulatory pathway, the enzyme γ-
glutamyl hydrolase removes glutamate groups from MTX, enabling the anti-
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metabolite to exit the cell through the multidrug resistance-associated channels 
(Danila et al., 2010). Figure 3b shows the structures of MTX and MTX-PG.  
 
 
Figure 3. Molecular structures of folic acid (3a), methotrexate (3a; 3b), and 
methotrexate polyglutamate (3c). FPGS = polyglutamyl synthetase; GGH = γ-
glutamyl hydrolase. The figure is taken from (Cronstein and Aune, 2020).   
 
Interestingly, while MTX has high bioavailability when given in less than 
7.5 mg/week doses, its bioavailability drops off as much as 30% when the 
dosage is increased to 15 mg/week or greater in patients with RA, suggesting 
that parenteral (subcutaneous or intramuscular) MTX has improved bioavailability 
relative to oral MTX (Hamilton and Kremer, 1997). The subcutaneous and 
intramuscular routes are interchangeable in terms of bioavailability (Brooks et al., 
1990). Following absorption and distribution, most MTX is excreted in urine within 
12 hours (Calvert et al., 1977). Common adverse effects reported in patients 
receiving low-dose MTX include nausea and vomiting (22%), infection (12%), 
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headache (8)%), elevated liver transaminases (7%), cold (6%), and fatigue (6%), 
leading approximately 10% of patients to discontinue this agent (Schröder and 
Stein, 2003). Many of the adverse events are believed to be associated with the 
anti-folate effect of MTX. Supplementation with folic and folinic acid reduces 
gastrointestinal adverse effects, increases patient compliance, and reduces liver 
transaminase levels while not reducing the efficacy of MTX (Whittle and Hughes, 
2004).  
Mechanisms of Action 
MTX was initially designed as a folate antagonist for use in the 
chemotherapeutic approach to malignancies. While it has shown anti-
inflammatory effect at lower doses, the dominant mechanism(s) through which 
this is achieved has not been established.  Several mechanisms could explain 
the immunosuppressive effect(s) of MTX, including decreasing purine and 
pyrimidine function, increasing adenosine release, methylation reactions, 
migration of nuclear factor-κB (NF-κB) into the nucleus, nitric oxide production, 
signaling of the JAK-STAT pathway, and the expression of non-coding RNA’s 
(Cronstein and Aune, 2020). 
Folate Antagonism 
The primary mechanism of action of MTX appears to be the suppression 
of purine and pyrimidine synthesis, which indirectly suppresses cell division. 
(Tian and Cronstein, 2007). After polyglutamation of MTX, MTX-PG inhibits 
dihydrofolate reductase (DHFR), which inhibits the subsequent conversion of 
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dihydrofolate to tetrahydrofolate (Cronstein and Aune, 2020). In addition, MTX-
PG suppresses the action of other enzymes, including methylenetetrahydrofolate 
reductase (MTHFR), thymidylate synthase (TYMS), and 5-aminoimidazole-4-
carboxamide ribonucleotide transformylase (ATIC), which all contribute to the 
decreased production of purine and pyrimidine synthesis (see Figure 4a). While 
this mechanism contributes to the cytotoxic effect of MTX, there is not sufficient 
evidence to indicate if this same mechanism also leads to anti-inflammatory 
effects. Many patients take folate supplementation to reduce the adverse effects 
of MTX therapy and do not experience any reduction in the drug's efficacy in 
treating their inflammatory illness. This observation suggests that other 
mechanisms may be operant concerning the anti-inflammatory effect(s) of MTX 
and MTX-PG.  
Adenosine Signaling 
Inhibition of ATIC by MTX-PG suppresses purine and pyrimidine 
synthesis, resulting in an accumulation of adenosine derivatives, one of the 
primary substrates of ATIC reaction (Cronstein and Sitkovsky, 2017). Inhibition of 
ATIC also leads to an increase in the concentration of aminoimidazole-4-
carboxamide ribonucleotide (AICAR), which further inhibit adenosine deaminase 
(ADA) and prevents the conversion of intracellular adenosine into inosine (see 
Figure 4b). This excess adenosine is transported out of the cell by the nucleotide 
transporter Ent1.  Here the adenosine acts in a paracrine fashion to bind and 
stimulate nearby adenosine receptors A1, A2a, A2b, and A3 (Hasko et al., 2008). 
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All 4 of these are G-protein coupled receptors, which signal downstream targets 
and trigger anti-inflammatory responses (Friedman and Cronstein, 2019). These 
effects are summarized in Figure 5.  
 
 
Figure 4. Mechanisms for folate antagonism and adenosine signaling. MTX, 
and more specifically, MTX-PGs, lead to cytotoxic effects through the anti-folate 
mechanism (4a) and anti-inflammatory effects through the adenosine release 
mechanism (4b). The antifolate mechanism involves inhibition of dihydrofolate 
reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR), thymidylate 
synthase (TYMS), and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
transformylase (ATIC), which cumulatively lead to reduction in the synthesis of 
purines and pyrimidines. The adenosine release mechanism involves the 
inhibition of adenosine deaminase (ADA). The figure is taken from (Cronstein 





Figure 5. Effects of adenosine signaling pathway on inflammatory cells. 
Receptors A1 and A2A have higher affinity for adenosine than receptors A2B and 
A3. The figure is taken from (Friedman and Cronstein, 2019).  
 
Generation of Reactive Oxygen Species 
The production of reactive oxygen species (ROS) may also contribute to 
the anti-inflammatory effect of MTX (Phillips et al., 2003). As previously 
mentioned, MTX-PG suppresses the action of the enzyme DHFR and thereby 
inhibits tetrahydrofolate production. Inhibition of DHFR also suppresses the 
conversion of oxidized dihydrobiopterin to tetrahydrobiopterin, a ligand of 
endothelial nitric oxide synthase (eNOS) (Brown et al., 2016). 
Tetrahydrobiopterin functions with eNOS to drive the synthesis of nitric oxide, but 
dihydrobiopterin uncouples from eNOS and instead leads to the production of 
superoxide species (Brown et al., 2016). The subsequent increase in ambient 
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cellular ROS activates c-Jun N-terminal kinase (JNK), which ramps up production 
of proteins that promote apoptosis in T-cells (Spurlock et al., 2011).  
Cytokines and Adhesion Molecules 
MTX decreases the formation of pro-inflammatory cytokines, such as IL-2, 
IL-4, IL-13, IFNγ, TNFα, and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), through its inhibitory effect on purine and pyrimidine synthesis 
(Gerards et al., 2003). Along with this, treatment with MTX in patients with RA 
increases the production and secretion of the anti-inflammatory cytokine IL-10 by 
regulatory T-cells (Rudwaleit et al., 2000). Finally, MTX therapy also appears to 
reduce the expression of vascular adhesions molecules essential to the 
recruitment and migration of inflammatory cells. Consistent with this finding, a 
six-month course of MTX treatment in patients with RA significantly decreased 
the levels of soluble E‐selectin, intercellular adhesion molecule‐1, and vascular 
cell adhesion molecule‐1 (Klimiuk et al., 2007).  
In aggregate, these mechanisms cumulatively contribute to the anti-
inflammatory effect of MTX. However, there is no consensus thus far on the 
dosing and route of administration for this agent.  The lack of data is likely related 
to the short half-life of MTX.  On the other hand, several studies have examined 
the utility of measuring MTX-PG, the active metabolite of MTX, to improve MTX 




CURRENT LITERATURE ON THE UTILITY OF METHOTREXATE 
POLYGLUTAMATE AS A BIOMARKER FOR THERAPY 
 
Studies on Inflammatory Bowel Diseases 
While there have been numerous studies measuring the correlation of 
MTX-PG levels and disease activity in patients with RA and psoriasis, only two 
studies have explored this relationship in patients with IBD (Brooks et al., 2007 
and Fisher et al., 2017). These two will be examined first, followed by a 
comparison of similar studies in other inflammatory diseases.  
Brooks et al. measured total and individual MTX-PG (MTX-PG 1,2,3,4 & 5) 
concentrations in patients with IBD. The goal of this study was to measure intra-
patient variability in MTX-PG concentrations at steady-state and to correlate 
these levels with measures of disease activity and adverse events. They 
recruited and followed 18 patients with IBD (CD, UC, or indeterminate colitis) 
over 6-7 weeks. Each patient was on a stable dose (15-25 mg) of MTX for at 
least three months, with most patients additionally taking folate supplementation, 
5-aminosalicylic acids, or corticosteroids. 78% of patients received MTX orally, 
while another 17% received it subcutaneously, while 1 patient received it via 
percutaneous endoscopic gastronomy. Disease activity for patients with CD and 
UC were measured using CDAI or the Simple Clinical Colitis Activity Index 
(SCCAI), respectively. A brief overview of SCCAI is shown in Table 6. Like the 
CDAI, the SCCAI relies on patients' reported symptoms and does not include 
measures of mucosal disease activity. For the CD group, eight patients (62%) 
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were in remission (CDAI: 150 or less), and five patients had active disease (CDAI 
> 150). In the UC group, two patients (50%) were in remission based on SCCAI, 
and the remaining two patients (50%) had active disease.  
 
Table 6. Simple Clinical Colitis Activity Index (SCCAI)* (adapted from the 
ECCO E-Guide) 
Bowel movements - day 0-3 (0); 4-6 (1); 7-9 (2); >9 (3) 
Bowel movements - night 0 (0); 1-3 (1); 4-6 (2) 
Fecal Urgency None (0); Hurry (1); Immediate (2) 
Incontinence (3) 
Bloody stool None (0); trace (1); occasional (2); frequent 
(3) 
Well-being Very well (0); slightly below par (1); poor (2); 
very poor (3); terrible (4) 
Number of extracolonic features None (0); 1 (1) 2 (2); 3 (3); 4 (4); 5 (5) 
SCCAI = sum of all points  
 
*Numbers in parenthesis indicate the points associated with each option. Less 
than 3 points indicate remission; a drop in 2 points indicates response. 
 
The data revealed that long-chain MTX-PG measurements (MTX-PG3-5) 
displayed an intra-patient variability of 15%. Further, inter-patient variability was 
generally over 50% for individual MTX-PG measurements and as high as 90% 
for MTX-PG5. Interestingly, in contrast to the study hypothesis, there was a 
significant direct correlation between CDAI scores and higher long-chain MTX-
PG4,5 levels, implying an elevation in MTX-PG is not uniformly sufficient to control 
mucosal disease activity in all patients. The investigators also noted that the 
concentration of MTX-PG4,5 levels did not differ in patients in clinical remission 
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from those with active disease. In contrast, elevated MTX-PG4,5 levels were 
related to the occurrence of gastrointestinal symptoms and other reported 
adverse events.    
The study by Fisher et al. looked specifically at patients with Crohn’s 
disease. Like Brooks et al., this study assessed the correlation between 
individual and total MTX-PG levels, disease activity, and adverse events. The 
study recruited 12 adult patients receiving a stable dose (25 mg) of MTX for at 
least 12 weeks. Of the 12 enrolled patients, 10 received MTX subcutaneously, 
and the remaining two orally.  All patients were taking folic acid supplementation, 
and three were receiving corticosteroids. Disease activity was measured clinically 
using the Harvey-Bradshaw Index (HBI) and biochemically, using the 
inflammatory markers CRP, fecal calprotectin, and erythrocyte sedimentation 
rate (ESR). The components included in the HBI are summarized in Table 7 
(Harvey and Bradshaw, 1980).  Notably, the HBI differs from the CDAI used in 
the Brooks study, which also includes data on the use of anti-diarrheal agents, 
hematocrit, and body weight. The Fisher study also used the SIBDQ.  The 












Table 7. Harvey-Bradshaw Index.* Table adapted from (Harvey and Bradshaw, 
1980).  
 
Well-being Very well (0); slightly below par (1); poor 
(2); very poor (3); terrible (4) 
Pain in abdomen None (0); mild (1); moderate (2); severe (3) 
Number of liquid stools (daily) ____ (number) 
Presence of mass in abdomen None (0); dubious (1); definitive (2); 
definitive/tender (3) 
Complications (arthralgia, uveitis, 
erythema nodosum, aphthous 
ulcers, anal fissure, fistula, 
abscess, pyoderma 
gangrenosum) 
1 point per complication 
HBI = total score (< 5: remission; 5-7: mild; 8-16: moderate; >16: severe) 
 
*Numbers in parenthesis indicate the points associated with each option. 
 
Data from the Fisher study did not support an association between 
individual or total MTX-PG levels and disease activity as measured by the HBI, 
biological markers of inflammation, or the SIBDQ. The study was cross-sectional 
and therefore unable to inform on intra-patient MTX-PG variability.  Nonetheless, 
the interpatient MTX-PG variability was considerable and as high as 28-fold 
between patients. Patients in clinical remission had lower median concentrations 
of long-chain MTX-PG than those with active disease. However, this relationship 
was not significant (p = 0.2).  
MTX has long been well-established as the first-line treatment of other 
inflammatory diseases, including Rheumatoid (RA) and Juvenile Inflammatory 
Arthritis (JIA) arthropathies. More data is available investigating the utility of 
MTX-PG as a biomarker of pharmacologic efficacy in these conditions. Data from 
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these studies may offer additional insight regarding the prospect of using MTX-
PG measurements to optimize therapy in patients with Crohn’s disease.  
Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is an inflammatory disease that primarily 
impacts the joints and results in joint damage over time. Specifically, it involves 
an increased presence of immune cells such as T-cells, B-cells, and monocytes 
in the synovial membrane, which leads to inflammation of the synovial membrane 
and resulting damage to both surrounding bone and cartilage (Aletaha et al., 
2011). Like CD, the pathophysiology of RA involves action of various pro-
inflammatory cytokines, such as TNF and IL-6, which facilitate the development 
of osteoclasts and result in bone erosion (Redlich and Smolen, 2012). While the 
cause(s) of RA is unknown, it is associated with certain genetic and 
environmental risk factors, which include presentation of certain HLA class II 
antigens, smoking, periodontitis, microbiome alterations, viral infections, and 
other factors (Aletaha and Smolen, 2018). Autoantibodies against autoantigens, 
such as anticitrullinated peptide antibodies (ACPAs) and antibodies to IgG 
(rheumatoid factor [RF]) may also promote inflammatory responses in RA by 
formation of immune complexes that induce the complement system (Aletaha 
and Smolen, 2018). Development and detection of these antibodies may be a 
predictor of RA several months to years before clinical symptoms manifest 
(Nielen et al., 2004).  
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Owing to the heterogenous nature of the disease, there is no diagnosis 
criteria for RA. However, in 2010, a classification criterion was developed by the 
European League Against Rheumatism (EULAR) and the American College of 
Rheumatology (ACR) for purposes of clinical research and may assist physicians 
with diagnosis as well (Aletaha et al., 2010). This classification considers joint 
evaluation, serology, acute-phase reactants (APR), and duration of symptoms 
and has a sensitivity and specificity of 82% and 61%, respectively (see 
Appendix III). As with CD, several indices have been developed to monitor 
disease activity in RA, which include the clinical disease activity index (RA-
CDAI), disease activity score using 28 joints (DAS28) or the Simplified Disease 
Activity Index (RA-SDAI) (Aletaha and Smolen, 2018). All these indices consider 
a combination of joint assessments, patient/physician assessment of disease and 
APR measures (summarized in Appendix IV).  
The medications used to treat RA are broadly called disease-modifying 
anti-rheumatic drugs (DMARDs) (Aletaha and Smolen, 2018). These drugs slow 
the progression of joint damage in RA and reduce disease activity, in addition to 
decreasing clinical symptoms from the disease. Further, these drugs can be 
broadly classified into synthetic and biologic DMARDs. Biologic DMARDs work 
through several mechanisms highlighted in Figure 6. Synthetic DMARDs include 
MTX, sulfasalazine (SSZ), leflunomide, hydroxychloroquine and Janus kinase 
(JAK) inhibitors (Aletaha and Smolen, 2018). Sulfasalazine is an analog of 5-
aminosalicylic acid (5-ASA) linked to sulfapyridine that acts as an anti-
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inflammatory agent by inhibiting formation of prostaglandins and leukotrienes and 
promoting accumulation of adenosine (Gadangi et al., 1996).  Leflunomide 
suppresses de novo pyrimidine synthesis by inhibiting the enzyme dihydroorotate 
dehydrogenase. MTX continues to be the standard first-line therapy in RA and is 
efficacious in 20-40% of RA patients (Aletaha and Smolen, 2018). However, 
there is not much consensus on the appropriate dosing of the drug. Therefore, 
several studies discussed below have evaluated the potential for MTX-PG – the 
stable, active metabolite of MTX – to serve as a therapeutic drug monitoring tool 





Figure 6: Biologic therapies used to treat rheumatic diseases. TNF inhibitors 
include infliximab, adalimumab, golimumab, etanercept and certolizumab pegol. 
Infliximab is a chimeric anti-TNF antibody. Adalimumab and golimumab are 
humanized anti-TNF antibodies. Etanercept is a TNF receptor-Fc fusion protein. 
Certolizumab pegol is a pegylated humanized anti-TNF antibody. Anakinra is an 
IL-1 receptor antagonist. Tocilizumab is an anti-IL-6 antibody. Abatacept is a 
Cytotoxic T-lymphocyte antigen-Fc fusion protein that inhibits T-cell co-
stimulation. Rituximab is an anti-CD-20 antibody. The figure is taken from 




Prospective Cohort Studies on Rheumatoid Arthritis 
Dervieux et al. completed a prospective study in 48 MTX naïve patients 
with RA (Dervieux et al., 2006). Participating patients were started on an initial 
dose of MTX (7.5 mg), which was gradually increased until a clinical response 
was achieved. The median dose for the study was 17.5 mg/week at six months. 
Patients in this study were taking a range of concomitant therapies, including 
folate supplementation, non-steroidal anti-inflammatory drugs (NSAIDs), 
sulfasalazine (SSZ), hydroxychloroquine, and corticosteroids.  
Disease activity was measured using DAS28. The study found a 
significant association between lower MTX-PG levels and less clinical 
improvement, as assessed by serial DAS28 measurements (Dervieux et al., 
2006). Patients experiencing less clinical improvement were receiving 
significantly higher doses of MTX. Data from this study also revealed that 
genotype MTHFR 677TT was associated with a lower response to MTX therapy.  
In contrast, the SHMT‐1 1420CC genotype was associated with a higher 
response to therapy. Interestingly, while MTX-PG metabolite levels did not 
predict the risk of side effects, higher doses of the parent drug (MTX) were 
significantly related to developing neurological symptoms.  
Stamp et al. investigated whether changing the route of administration 
(from oral to subcutaneous) had any effect on MTX-PG metabolite levels, 
disease activity, or adverse effects (Stamp et al., 2011). The bioavailability of 
MTX falls as the dose rises above 15 mg (Hamilton and Kremer, 1997). Thirty 
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patients who were not responding to or experienced adverse events from oral 
MTX therapy were enrolled in this study. Enrolled patients were switched from 
oral to subcutaneous (SC) MTX administration and followed for 24 weeks. For 
detailed patient characteristics for this study and others discussed in this section, 
see Appendix II. Clinical response to therapy was measured using DAS28 
scores.  
The transition from oral to SC administration was sufficient to significantly 
increase the concentrations of intracellular MTX-PG1-5(total), MTX-PG3, MTX-
PG4, MTX-PG5, and MTX-PG3-5. This finding was associated with significant 
improvements in disease activity, as assessed by swollen joint count (SJC), pain 
visual analog scale (VAS), patient global score, and modified Health Assessment 
Questionnaire (mHAQ).  Increased MTX-PG5 and MTX-PG3-5 levels were also 
significantly correlated with a reduction in DAS28 scores. Finally, 
pharmacokinetics revealed that it took about 34 weeks to reach 90% of steady-
state for long-chain MTX-PG metabolites delivered SC.  In a preceding study, it 
took 41, 149, and 139 weeks via the oral route to reach 90% of steady-state for 
MTX-PG 3,4 and 5, respectively (Dalrymple, et al., 2008).   
De Rotte et al. conducted a prospective longitudinal study to identify 
associations between MTX-PG concentrations and disease activity, which was 
primarily measured by DAS28 scores (De Rotte et al., 2015).  The study included 
a derivation cohort (n= 108 patients) and a validation cohort (n= 285 patients) 
and controlled for patient characteristics, including the use of concomitant 
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therapies. Patients in the validation cohort received a higher mean dose of MTX 
(25 mg/week) than those in the derivation cohort (15 mg/week). This disparity 
initially resulted in significantly higher concentrations of long-chain MTX-PG and 
total MTX-PG at six months in the validation cohort. However, this difference was 
not noticeable at nine months.  Longitudinal analysis completed in the derivation 
cohort found an association between lower DAS28 scores and MTX-PG1, MTX-
PG2, MTX-PG3, and total MTX-PG levels. In contrast, MTX-PG2, MTX-PG3, MTX-
PG4, and total MTX-PG were associated with lower DAS28 scores in the 
validation cohort. The study also established an MTX-PG2 level of >22 nmol/L 
and a total MTX-PG concentration >74 nmol/L as thresholds predicting a positive 
clinical response. While adverse events were reported in both study cohorts, the 
rates declined with time.  
Cross-Sectional Studies on Rheumatoid Arthritis 
Angelis-Stoforidis et al. completed a cross-sectional study in 65 patients 
with RA to evaluate MTX-PG levels in circulating erythrocytes, mononuclear 
cells, and polymorphs (Angelis-Stoforidis et al., 1999). All patients had been on 
MTX therapy for at least two months. Clinical assessment was not assessed by 
DAS28 in this case, but instead on the physician’s global clinical assessment of a 
patient’s joint conditions, history, and composite clinical assessments. Patients in 
this study were then stratified, based on their clinical response, as responders, 
partial responders, and non-responders. The investigators found that RBC MTX-
PG levels were significantly higher in the responder and partial responder groups 
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than those measured in non-responders. The responders and non-responders 
had total RBC MTX-PG levels of 61 nmol/L and 51 nmol/L respective. However, 
the inter-patient variability continued to be high, consistent with other studies 
discussed here. Levels of specific MTX-PG levels were not recorded in this 
study. Finally, the MTX dose itself was not correlated with MTX-PG levels, and 
non-responders were generally taking higher doses of the drug.  
 Dervieux et al. conducted a multi-center cross-sectional study on the 
effect of MTX-PG levels and a pharmacogenetic index on the disease status of 
RA patients (Dervieux et al. 2005). 226 patients receiving a stable dose of MTX 
treatment for at least three months were enrolled in the study. Exclusion criteria 
included concomitant DMARD therapy, thus avoiding a confounding effect on 
disease status. Instead of DAS28, a reduced 22 joint count was used, along with 
mHAQ and 10 cm VAS (0 = excellent response to MTX, 10 = no response). 
Further, MTX-PG3 was itself used as a proxy for long-chain MTX-PGs as it is the 
most abundant out of the three. The median MTX-PG3 concentration was 40 
nmol/L, but with a high inter-patient variance (range: <2 – 135 nmol/L)  consistent 
with the other studies examined thus far. A total MTX-PG level of less than 60 
nmol/L was significantly associated with an inadequate clinical response. This 
level was consistent with that reported by Angelis-Stoforidis et al. and slightly 
below the cutoff of 74 nmol/L reported by De Rotte.  
 Stamp et al. completed a cross-sectional study to establish a therapeutic 
range for MTX, along with thresholds for treatment efficacy as well as adverse 
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effects (Stamp et al., 2010). The study included 192 patients with RA who had 
been receiving oral MTX for at least three months and stable dosing for at least 
one month. Metrics used to track clinical response in this study included DAS28, 
TJC, SJC, 100-point VAS, RA-CDAI, and RA-SDAI. Unlike previous RA studies, 
but consistent with two prior IBD studies, Stamp and colleagues standardized 
concentration measurements against an RBC count of 8 x 1012 instead of 
volume. All patients received oral prednisone and were on a wide range of 
concomitant therapies, details of which are available in Appendix II.  
 Data from this study revealed a significant and positive association 
between MTX dosage and levels of individual and cumulative measurements of 
long-chain MTX-PG (MTX-PG3-5) and total MTX-PG.  Higher MTX dosing was 
also significantly associated with poor clinical response, as assessed by SJC, 
physician and patient global assessment score, DAS28, RA-CDAI, and RA-SDAI. 
A follow-up prospective cohort study completed by this group a year later 
demonstrated a significant and inverse correlation between MTX-PG levels and 
disease activity. Similar to that reported by Dervieux and colleagues, MTX-PG3 
was the most abundant MTX-PG species. While most participants (74%) 
reported at least one adverse event, there was no significant relationship 
between the occurrence of these adverse events and the dosage of MTX that a 
patient was receiving.  
 Ando et al. conducted a cross-sectional study that included 145 patients 
with RA to assess how differences in MTX-PG could explain the differential 
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response to MTX therapy (Ando et al., 2013). The study found no significant 
associations between any MTX-PG species and disease activity as assessed by 
DAS28. However, the mean MTX dose for patients in this study was 8.3 (4.0-
15.0),  and this was the lowest out of all the prospective and cross-sectional 
studies reviewed. While MTX-PG1-3 were detectable in all patients, MTX-PG4 and 
MTX-PG5 were only detectable in 51% and 17% of patients, respectively. The 
detection of MTX-PG 5 was significantly higher in responders compared to non-
responders. No information was provided regarding the duration of disease in 
patients enrolled in the study or the range of time they were on MTX treatment. 
Given this lack of information, it is possible that patients in the study may not 
have been on MTX therapy for a long-enough duration to reach stable 
intracellular long-chain MTX-PG levels. 
Juvenile Idiopathic Arthritis 
Juvenile idiopathic arthritis (JIA) is a chronic rheumatic illness of unknown 
origin, whose symptoms present before the age of 16 and remain persistent for 
at least six weeks (Petty et al., 2004). JIA can be further distinguished into more 
specific disease groups based on factors such as clinical symptoms, effective 
treatments, and prognosis of disease (Barut et al., 2017). These include systemic 
arthritis, oligoarthritis, polyarthritis (RF positive or negative), psoriatic arthritis, 
enthesitis related arthritis and undifferentiated arthritis (Petty et al., 2004). RF-
positive polyarthritis, which is the analog of adult rheumatoid arthritis, only occurs 
in 10% of pediatric patients (Barut et al., 2017).  
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Just as with IBD and RA, the cause of JIA is unknown. It is hypothesized 
to occur in patients with genetic predispositions who may also be exposed to 
stress, joint injury, abnormal hormone levels, bacterial and viral infections (Weiss 
and Ilowite et al., 2007). Presence of certain HLA class I and II alleles, anti-
nucleotide antibodies (ANA), RF, and complement activation is commonly found 
in certain disease subtypes (Weiss and Ilowite et al., 2007). Finally, elevated 
levels of cytokines such as interleukin-6 (IL-6) and TNF-alpha and correlated 
elevations in CRP are also observed in these patients (TL, 1999; Weiss and 
Ilowite et al., 2007).  
Several tools exist to assess disease activity in JIA, and those used most 
widely in practice include the Juvenile Arthritis Disease Activity Score (JADAS) 
and the Childhood Health Assessment Questionnaire (CHAQ) (Barut et al., 
2017). JADAS incorporates several measures such as the physician and patient 
global assessment (using a 10 cm VAS), active joint count and APRs (ESR or 
CRP) (Consolaro et al., 2016). This score has defined cutoff values to 
differentiate between inactive disease and varying levels of active disease (low, 
moderate, or high).  
Common medications for treating JIA include NSAIDs, corticosteroids and 
DMARDs (synthetic and biologic). NSAIDs such as ibuprofen are primarily used 
in children under the age of 12 and provide both analgesic and anti-inflammatory 
effects (Barut et al., 2017). Corticosteroids are more potent anti-inflammatory 
agents but are limited in their use due to their associated side effects. However, 
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these two classes of medications do not prevent joint damage and are used 
concomitantly with biologic and non-biologic DMARDs.  
Biologic DMARDs work through several different mechanisms highlighted 
in Figure 6. Non-biologic DMARDs include SSZ, leflunomide and methotrexate. 
MTX is the most common non-biologic DMARD used in the treatment of JIA, 
however, there still remains significant variability in response to the drug, which 
has prompted research into optimal dosing, route of administration and 
biomarkers such as MTX-PGs to enhance individualized therapy in patients 
(Kessler and Becker, 2014). 
Prospective Cohort and Cross-Sectional Studies on Juvenile Idiopathic Arthritis 
 Calasan et al. conducted a prospective cohort study to assess the 
association between MTX-PG levels and disease activity in patients with JIA 
(Bulatovic Calasan et al., 2013). In total, 113 MTX-naïve patients were studied. 
Measurements of MTX-PG levels and disease activity were assessed at three 
months and one year. Disease activity was assessed using the Juvenile Arthritis 
Disease Activity Score of 27 joints (JADAS27). There was a significant 
association between MTX-PG3, MTX-PG4, MTX-PG5, and MTX-PG3-5 levels and 
lower JADAS27 scores noted at three months. The concentrations of MTX-PG4 
and MTX-PG5 were considerably lower, likely indicating that these more heavily 
glutamated MTX-PG moieties may take longer to achieve steady-state 
intracellular levels. Besides the native MTX-PG1, MTX-PG3 was the most 
abundant moiety present at three months and accounted for 32% of the total 
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concentration of  MTX-PG. Longitudinal analysis at one year found that higher 
levels of each of the individual long-chain MTX-PG and aggregate MTX-PG3-5 
concentrations were associated with lower JADAS27 scores.   
 In contrast to the Calasan study, a cross-sectional study by Dolezalova et 
al. demonstrated a significant relationship between MTX dose and total MTX-PG 
concentration (Dolezalova et al., 2005). Still, it failed to confirm the correlation 
between total MTX-PG concentrations and disease activity. However, this study 
included only 30 patients, and the range of duration on MTX therapy was quite 
broad (between 3 months and five years). Further, 53% of patients in this study 
received oral MTX while the rest received it via the subcutaneous route. The 
patients receiving MTX via the subcutaneous route received a significantly higher 
MTX dose and had significantly higher total MTX-PG concentrations. There was 
a trend toward higher MTX and total MTX-PG levels in patients with an 
inadequate clinical response.  Individual MTX-PG levels were not measured in 
this study. As such, it is unclear as to whether or not the discrepant response 
was related to discordant oral and parenterally treated patients, the difference in 
dosage or bioavailability, or disproportionately increased levels of (less 









The extent to which individuals can enzymatically glutamate MTX is likely 
to explain at least some of the observed varied responses to therapy.  Most 
studies to date, particularly those conducted in patients with RA, have displayed 
a negative relationship between long-chain MTX-PG levels and clinical disease 
activity. However, the findings reported by Brooks et al. did not support this 
paradigm. Several reasons may explain this discrepancy. First, the study was not 
conducted with a sufficiently large sample size. There were only 4 UC, 13 CD, 
and one patient with indeterminate colitis. Additionally, patients in this study 
received MTX both orally and parenterally, and previous data have demonstrated 
that the bioavailability of MTX can differ significantly at doses above 15 mg. The 
indices used to measure disease activity, including the CDAI and SCCAI, are 
symptom-based and therefore susceptible to report bias and subjective 
interpretations. The inclusion of indices that assess mucosal healing, such as 
CDEIS and SES-CD, would help provide additional objective information about 
the disease activity in studied patients.  
Fisher and colleagues did not find a significant association between levels 
of long-chain MTX-PG and disease activity. However, this study was conducted 
with an even smaller sample size of 12 patients. This study also did not 
incorporate endoscopic indices for Crohn’s disease.  While more labor-intensive, 
these objective metrics of mucosal disease activity may provide important 
information about disease localization and mucosal healing that is not reflected in 
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patient-reported indices, including the CDAI and HBI. Given the heterogeneous 
nature of CD, studies incorporating these variables could be valuable. 
Interestingly, although all of the patients in this study were treated with the same 
MTX dose, there was considerable interpatient variability in MTX-PG levels. 
Patient BMI was not reported in this study, but this measurement may explain the 
discrepant pharmacologic MTX-PG outcome measures along with oral vs. 
parental dosing.  
The results of the Dervieux study demonstrated an association between 
higher MTX-PG levels and more improvement in DAS28 scores.  However, the 
study did not differentiate between long and short-chain MTX-PG levels. Data 
from this study also begins to explain how genetic factors play a role in 
determining the response to therapy in patients being treated with MTX.  
The data from the study by Stamp demonstrated that steady-state levels 
of long-chain MTX-PG are achieved more quickly and reach significantly higher 
concentrations in patients being treated with parenteral (subcutaneous) MTX. 
These pharmacokinetic data are particularly relevant to this agent's use in 
managing patients with Crohn’s disease. The most practical regimen may include 
induction with parenteral MTX followed by a course of maintenance therapy with 
oral MTX.  
The de Rotte et al. cohorts afford some insights into the relationship 
between MTX dosing and red blood cells (RBCs) MTX-PG levels. Notably, this 
study's data did not suggest a dose-response relationship between MTX and 
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adverse effects.  This suggests that clinicians could consider forgoing traditional 
gradual dosage escalation, start with a higher dose, and more quickly reach 
therapeutic steady-state MTX-PG.  Interestingly, this study also found the 
strongest association of disease activity with levels of less (MTX-PG 2 and MTX-
PG3) rather than more (MTX-PG4 and MTX-PG5) MTX derivative metabolites. 
 Data from the Angelis-Stoforidis study supported an association between 
MTX-PG levels and disease activity.  However, this study employed the 
physician’s global assessment of the patient, not the more traditional DAS28, to 
assess disease activity.  The total MTX-PG levels for responders (61 n/mol/L) 
and partial responders (51 n/mol/L) in this study were lower (74 nmol/L) than 
those reported for responders in the de Rotte study.  No significant association 
was found between the dosing of MTX and MTX-PG levels. Further research is 
necessary to understand better the interaction(s) between bioavailability, 
metabolism, and genetic factors involved in the pharmacokinetic conversion from 
MTX and total and species-specific MTX-PG.   
 The cross-sectional study by Dervieux et al. identified an MTX-PG  
threshold of 60 nmol/L as a predictor of a favorable response to therapy.  This 
cutoff was consistent with findings reported by Angelis-Stoforidis.  However, the 
cross-sectional study design, and the considerable heterogeneity in the duration 
of MTX therapy of enrolled patients, likely contributed to the considerable 
variability in measured levels of MTX-PG3, which served as the proxy 
measurement for long-chain MTX-PG reported by the authors.  Like the results 
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reported in the Angelis-Stoforidis study, there was a trend towards patients with 
poor clinical responses being treated with higher MTX doses. This finding could 
be explained by either a gradual dose escalation in patients that fail to respond to 
the drug or little dose escalation in those that initially respond very well to the 
drug. The availability of MTX-PG (total or specific) levels that can serve as 
therapeutic benchmarks could individualize MTX therapy and more objectively 
identify non-responders who can then be more expediently transitioned to 
alternative therapies.   
 The cross-sectional study by Stamp et al. found a significant association 
between MTX dosing and levels of long-chain and total MTX-PG levels. 
However, these higher levels of MTX-PG were associated with more significant 
clinical disease activity. This conclusion was then reversed in a follow-up 
prospective study completed by this group.  These discordant results illustrate 
the limitations of applying data collected in cross-sectional studies to answer 
questions about treating chronic diseases, including RA and IBD. For example, 
the more significant disease activity observed in patients receiving higher doses 
of MTX over time suggests that there is a subgroup of patients that are MTX-
resistant and unlikely to respond to dose escalation. Therapeutic drug monitoring 
using MTX-PGs could help identify non-responders earlier in the course of their 
disease and hopefully before the development of end-stage complications.  
Data from both the Dervieux and Stamp groups identified MTX-PG3 as the 
most abundant MTX derivative. Additionally, the de Rotte study further concluded 
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MTX-PG3 to be the most reliable predictor of all the MTX-PGs. However, they 
noted it takes about six months of therapy to reach steady-state concentrations. 
De Rotte proposed that MTX-PG2 may be more useful as a predictor of 
therapeutic response due to its relatively shorter time (about three months) to 
reach steady-state levels. However, because MTX-PG2 has a shorter half-life 
than MTX-PG3, it may have a higher measurement variance. Further, most 
studies have not found MTX-PG2  levels related to disease activity, unlike MTX-
PG3 and other longer-chain MTX-PG.  
 The Calasan study in patients with JIA provided further evidence that 
MTX-PG3 has the potential to be used clinically in guiding changes in MTX 
dosing. They reported significantly lower disease activity at three months, and 
this is a reasonable interval for therapeutic drug monitoring in a clinical setting. 
However, evidence-based therapeutic targets for aggregate and individual MTX-
PG levels have not been defined.  High inter-patient variability continues to 
hamper these pharmacokinetic efforts. Findings from further investigations into 
genetic or metabolic factors that direct MTX glutamation could assist clinicians in 
making rational dosing changes to reach therapeutic levels of MTX-PG, which 
may vary from patient to patient and from disease to disease.  
 There was a trend toward higher MTX and MTX-PG levels in poorly 
responding patients in the Dolezalova et al. study.  This offers further support for 
the hypothesis that a subgroup of MTX-resistant patients could benefit from 
switching to a different therapy early in the course of their illness if the MTX-PG 
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suggests further dosage escalation is likely to be futile (Dolezalova et al., 2005). 
The duration of MTX therapy was considerable in this study.  This makes any 






 The two studies in the literature examining the association between 
methotrexate polyglutamates and inflammatory bowel diseases were cross-
sectional, and this study design presents some limitations. These include the 
enrollment of patients receiving a broad range of MTX doses and for varied 
treatment duration and the inclusion of data from patients treated with escalating 
doses of MTX in vain efforts to achieve a response in those with 
pharmacologically or mechanistically MTX-resistant disease. Therefore, better-
defined prospective cohort studies that included larger sample sizes would allow 
for control over these factors and enable investigators to understand better the 
association between MTX-PG and disease activity in patients with Crohn’s 
disease.  
Further, given the heterogeneous nature of Crohn’s disease, these 
prospective cohort studies should go beyond symptom-based metrics like CDAI 
to include assessments of endoscopic disease activity and biochemical markers 
of inflammation. MTX is used as maintenance therapy in Crohn’s and is most 
often prescribed orally. However, given the significantly higher bioavailability and 
reduced time necessary to achieve steady-state long-chain MTX-PG levels using 
the parenteral route, the relative benefits of this administration route should be 
considered in the future studies. 
 MTX remains a first-line therapy for many rheumatologic diseases, 
including RA and JIA. However, in CD, it is primarily prescribed as an adjunct 
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therapy to enhance and telescope the efficacy of biologic therapies such as 
infliximab and adalimumab. While current literature points to parenteral MTX 
monotherapy's effectiveness in the maintenance of remission in Crohn’s disease, 
there is no consensus on proper dosage. The measurement of MTX-PG could be 
used as a clinical tool, especially early on in treatment, to guide the dosing of 
MTX and optimize treatment decisions. Some patients may require relatively 
small MTX doses to develop therapeutic MTX-PG levels. In contrast, other 
patients may have persistently low MTX-PG levels despite high MTX dosage and 
need to be transitioned to another medication to maintain remission, avoid 
relapse, or develop complications of the disease, including mucosal inflammation 
perforation or stricture. However, to accomplish this, threshold levels of MTX-
PGs need to be determined by conducting well-designed prospective longitudinal 
trials. This may prove challenging given the high interpatient variability of these 
active metabolites in patients on similar MTX dosages. 
Further research on MTX dosing and metabolism is necessary to enable 
more personalized treatment for each patient. Finally, randomized controlled 
trials will be needed to determine to be conducted in patients to evaluate if MTX-
PG therapy results in an improved clinical outcome relative to conventional 
therapy. These data will help validate the use of methotrexate polyglutamates 
levels as a useful tool in the clinical management of patients with Crohn’s 





The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a tool designed 
to measure and track quality-of-life in patients and is extensively used with those 
who have Crohn’s disease. It focuses on the emotional and social aspects of 
disease activity (adapted from Irvine et al., 1996). The total score for the SIBDQ 
ranges from 0 to 7 (worst to best). 
 
Questions (pertain to the last two weeks before 
answering the questionnaire) 




Hardly ever (2)  
A little of the time (3) 
Sometimes (4) 
A good bit of the time (5) 
Most of the time (6) 
All the time (7) 
 
How often have you felt fatigued or worn out? 
 
(1) (2) (3) (4) (5) (6) (7) 
How often have you delayed/canceled a social 
engagement because of bowel problems? 
(1) (2) (3) (4) (5) (6) (7) 
How often have you had difficulty engaging in 
leisure or sports activities due to your bowel 
problems? 
(1) (2) (3) (4) (5) (6) (7) 
How often have you had pain in your abdomen?  (1) (2) (3) (4) (5) (6) (7) 
How often have you felt depressed/discouraged? 
 
(1) (2) (3) (4) (5) (6) (7) 
How often have you passed excess amount of 
gas? 
(1) (2) (3) (4) (5) (6) (7) 
 
How often have you had trouble keeping/achieving 
your desired weight? 
(1) (2) (3) (4) (5) (6) (7) 
How often have you felt relaxed? (1) (2) (3) (4) (5) (6) (7) 
How often have you felt the urge to use the toilet 
despite your bowel being empty 
(1) (2) (3) (4) (5) (6) (7) 
 
How often have you felt anger caused by your 
condition? 
(1) (2) (3) (4) (5) (6) (7) 













The following table, adapted from (Aletaha et al., 2010), gives an overview of the 
classification criteria for RA:  
Patients being evaluated should have at least one joint with synovitis that is 
unlikely to be caused by another disease such as systemic lupus erythematosus, 
psoriatic arthritis, and gout. Definite RA is classified as a score of 6 or more (out 
of 10).  
  Score 
A. Joint (swollen or 
tender) 
1 large joint (shoulders, hips, knees, ankle) 0 
 2-10 large joints 1 
 1-3 small joints (with or without large joint 
involvement) 
2 
 4-10 small joints (with or without large joint 
involvement) 
3 
 >10 joints (at least 1 small joint involvement) 5 
B. Serology (-) RF and (-) ACPA 0 
 (low +) RF or (low + ACPA) 2 
 (high +) RF or (high + ACPA) 3 
C. APR (one 
needed) 
Normal CRP and ESR 0 
 Abnormal CRP or ESR 1 
D. Duration of 
symptoms 
Less than 6 weeks 0 
 6 weeks or more 1 
Total Score   
 
Abbreviations: ACPA: anti-citrullinated protein antibody; CRP: C‐reactive protein; ESR:  








Summary of the major indices for measuring disease activity in RA, adapted from 
(Aletaha and Smolen, 2018).  




] + 0.7*ln(ESR) 
+ 0.014*GH 
SJC28 + TJC28 + 
PGA + EGA + CRP 
SJC28 + TJC28 + 





/ LDA / 
MDA / 
HDA 




DAS28 < 3.2: 
good 
 











Abbreviations: ESR: erythrocyte sedimentation rate; GH: global health (or patient global 
assessment); HDA: high disease activity; LDA: low disease activity; MDA: moderate disease 
activity; PGA: patient global assessment; SJC28: swollen joint count of 28 joints; TJC28: tender 
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